Skip to content
Screener

Krystal Biotech, Inc. KRYS Common Stock Par Value Per Share

Common Stock Par Value Per Share at other companies

Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$0.010.0%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$0.000.0%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$0.010.0%
CNT
Canton Strategic HoldingsCNTN
$0.000.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$116.4M+31.9%
Operating income$53.7M+48.1%
Net income$55.9M+56.5%
EPS (diluted)$1.83+52.5%

Balance sheet

See full
Cash & equivalents$501.3M+62.4%
Total debt$9.1M-5.7%
Total equity$1.3B+29.7%
Total assets$1.4B+30.0%

Cash flow

See full
Operating cash flow$80.4M+160%
CapEx$7.1M+15.2%
Free cash flow$73.2M+196%

Valuation

See full
Market cap$9.55B+143%
Enterprise value$9.06B+152%
P/E42.4×+15.6×
P/S22.9×+11.9×

Profitability

See full
Operating margin42.8%+10.2pp
Net margin53.9%+16.7pp
FCF margin56.9%+16.5pp

Returns & leverage

See full
Return on equity19.9%+6.0pp
Debt / equity0.0×
Current ratio9.5×-0.2×

Where this comes from

Reported directly by Krystal Biotech, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 7:06 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001711279-26-000043
(in thousands, except par value)March 31,2026December 31,2025
Total liabilities120,238114,234
Commitments and contingencies (see note 7)
Stockholders’ equity
Common stock; $0.00001 par value; 80,000 shares authorized as of March 31, 2026 and December 31, 2025; 29,437 and 29,192 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively.
Additional paid-in capital1,198,2571,194,261
Accumulated other comprehensive (loss) gain(1,623)1,136
Retained earnings80,09524,163
Total stockholders’ equity1,276,7291,219,560

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Krystal Biotech, Inc.'s common stock par value per share?
Krystal Biotech, Inc. (KRYS) reported common stock par value per share of $0.00 in Q1 2026.
How has Krystal Biotech, Inc.'s common stock par value per share changed year-over-year?
Krystal Biotech, Inc.'s common stock par value per share decreased by 0.0% year-over-year, from $0.00 to $0.00.
What is the long-term trend for Krystal Biotech, Inc.'s common stock par value per share?
Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s common stock par value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0.00 to $0.00.
What does common stock par value per share mean?
The par value of common stock is the arbitrary legal value assigned to each share of common stock at the time of issuance. It is a legacy accounting requirement that has little impact on the actual market value or trading price of the shares.

Ask your AI about Krystal Biotech, Inc.'s common stock par value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude